138 related articles for article (PubMed ID: 23970983)
1. Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.
Morrell R; Langabeer SE; Smyth L; Perera M; Crotty G
Case Rep Hematol; 2013; 2013():729327. PubMed ID: 23970983
[TBL] [Abstract][Full Text] [Related]
2. MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.
Akpınar TS; Hançer VS; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2013 Mar; 30(1):8-12. PubMed ID: 24385746
[TBL] [Abstract][Full Text] [Related]
3. Expanded molecular detection of MPL codon p.W515 and p.S505N mutations in myeloproliferative neoplasms.
Miller EW; Lamberson CM; Akabari RR; Nasr MR; Sperber SM
J Clin Lab Anal; 2023 Dec; 37(23-24):e24992. PubMed ID: 38058281
[TBL] [Abstract][Full Text] [Related]
4. Detection of MPL mutations by a novel allele-specific PCR-based strategy.
Furtado LV; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2013 Nov; 15(6):810-8. PubMed ID: 23994117
[TBL] [Abstract][Full Text] [Related]
5. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
6. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
7. MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia.
Sugimoto Y; Nagaharu K; Ohishi K; Nakamura M; Ikejiri M; Nakatani K; Mizutani M; Tamaki S; Ikeda T; Tawara I; Katayama N
Int J Hematol; 2021 May; 113(5):618-621. PubMed ID: 33770389
[TBL] [Abstract][Full Text] [Related]
8. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
[TBL] [Abstract][Full Text] [Related]
9. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
10. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.
Dos Santos LC; Ribeiro JC; Silva NP; Cerutti J; da Silva MR; Chauffaille Mde L
Rev Bras Hematol Hemoter; 2011; 33(6):417-24. PubMed ID: 23049357
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
[TBL] [Abstract][Full Text] [Related]
15. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms.
Yu C; Yang Q; Chen Y; Wang D; Levine R; Crispino J; Wen Q; Huang Z
Cell Biosci; 2016; 6():34. PubMed ID: 27222706
[TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Pósfai É; Marton I; Király PA; Kotosz B; Kiss-László Z; Széll M; Borbényi Z
Pathol Oncol Res; 2015 Jul; 21(3):751-8. PubMed ID: 25573593
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia.
Liu K; Martini M; Rocca B; Amos CI; Teofili L; Giona F; Ding J; Komatsu H; Larocca LM; Skoda RC
Haematologica; 2009 Oct; 94(10):1368-74. PubMed ID: 19608689
[TBL] [Abstract][Full Text] [Related]
19. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
